Page 150 - CW E-Magazine (3-9-2024)

Pharmaceuticals Pharmaceuticals

INORGANIC GROWTH COLLABORATION
Zydus acquiring 50% stake in Sterling Biotech Dr. Reddy’s, Aurigene and Kainomyx join up

Zydus Lifesciences said it has inked biotech products for health and nutri- for developing anti-malarials
a pact with Perfect Day Inc, a Temasek tion, specifi cally catering to consumers
portfolio company, to acquire 50 per- who prefer animal-free protein or suffer Dr. Reddy’s Laboratories, along Kainomyx will offer a platform that
cent stake in Sterling Biotech. Post from lactose intolerance, the Gujarat- with its CRDMO arm Aurigene Pharma targets the cytoskeletal proteins of para-
the transaction, Sterling Biotech will based fi rm said. ceutical Services Ltd., has entered sites, representing a new mechanism
become a 50:50 joint venture with into a non-binding memorandum of of action in the fi ght against malaria.
equal representation on the Board, Zydus Perfect Day’s precision-fermented understanding (MoU) with US-based
Lifesciences said in a statement. While protein is found in ice creams, cream Kainomyx to co-develop and co-com- Mr. James Spudich, Executive
fi nancial details of the deal were not art manufacturing facility to manufac- cheese, sports nutrition products, and mercialise an affordable anti-malarial Chairman of Kainomyx, said, “New
disclosed, media reports pegged the ture fermented animal-free protein to baked goods with high functionality drug. The collaboration aims to ad- drug discovery for malaria and other
transaction at Rs. 550-crore. cater to the global markets. The jv will benefi ts and lower environmental dress the needs of patients in Europe, dite the development programme for parasitic diseases is essential because
accelerate the production of high-qua- impact. the US, and low and middle-income this new anti-malarial treatment. This drug resistance to existing therapeu-
Sterling Biotech is one of the lead- lity and eco-friendly protein products, countries. potential partnership aims to bring tics is rapidly developing. Through our
ing producers of pharmaceutical gela- reduce environmental impact, and cater “We are dedicated to promoting together Kainomyx’s expertise in novel decades of work, we have developed a
tine, di-calcium phosphate and some to the growing consumer demand growth through partnerships and are The MoU, which is pending a defi ni- drug discovery, Aurigene’s capability deep understanding of how cytoskeletal
APIs with two manufacturing facilities for fermentation-based and ethically consistently exploring new collabo- tive agreement, outlines a shared com- to conduct integrated drug discovery proteins work. Cytoskeletal proteins are
in Gujarat. sourced nutrition,” Zydus said in a rations to position India as a premier mitment to driving a comprehensive and development, and Dr. Reddy’s essential for all living organisms, and
regulatory fi ling. The acquisition also global supply chain hub,” Zydus Life- research and development agenda. By ability to commercialise products in low we are exploiting this to specifi cally
“The jv will establish a state-of-the- marks Zydus’ foray into specialised sciences’ MD Mr. Sharvil Patel said. leveraging the unique strengths of each and middle-income countries, in addi- target the cytoskeleton for treatment of
partner, the collaboration will expe- tion to the US and Europe. malaria.”
FATAL ACCIDENT
Pharma factory explosion in Andhra Pradesh kills SMOOTHER EXPORTS

at least 17 Argentina simplifi es norms for Indian pharmaceuticals

At least 17 people were reported located on a 40-acre campus within the Therefore, staff presence was less,” Argentina has moved to facilitate latory authorities parti-
to have died in a reactor explosion on Andhra Pradesh Industrial Infrastructure Ms. Krishnan was quoted as saying in news easy imports of pharmaceuticals from cularly from the US and
August 21 at pharma fi rm, Escientia Corporation’s (APIIC) multi-product reports. While initial reports suggested the India into the South American country. Europe, the registration
Advanced Sciences Pvt. Ltd. in Atchuta- SEZ at the Atchutapuram cluster. accident was due to a reactor blast, offi - of their products could
puram, Anakapalli district, Andhra Pradesh. cials said that the incident occurred when The Pharmaceutical Export Promo- be undertaken in a simple
A total of 41 people were injured. According to Anakapalli District solvent oil was being pumped between tion Council (Pharmexcil) said it has and speedy manner. “Ac-
Collector Ms. Vijaya Krishnan, the fi re fl oors, causing a leak that led to a fi re and received a communication from the cordingly, we encourage
The company manufactures inter broke out at 2:15 pm. “The factory ope- a subsequent large explosion, according Ambassador of India to Argentina and our member companies to
mediate chemicals and active pharma- rates with 381 employees in two shifts. to a post on X by Andhra Pradesh Deputy Uruguay on the measures taken by begin registering their
ceutical ingredients (APIs). The factory is The blast occurred during lunch time. Chief Minister Konidala Pawan Kalyan. Argentina authorities to facilitate products with the national
smoother and larger exports of Indian authority of Argentina,”
Sun Pharma to invest $15-mn in Pharmazz pharmaceuticals to Argentina. has a large number of laboratories that Mr. Raja Bhanu, Director General,
Pharmexcil said in a circular.
have approvals from the global regu-
Sun Pharmaceutical Industries thaquine for treatment of hypovolemic As part of the measures, if an Indian
has agreed to invest up to $15-mn in shock. Both products are approved in laboratory has a relevant certifi cation Arunish Chawla gets additional
Pharmazz to acquire more than 5% India and marketed through partners under of compliance with GMP issued by a
holding in the US-based fi rm, brands, Tyvalzi (Sovateltide) and Lyfaquin high-level health surveillance agency charge of Chairman, NPPA
(Centhaquine) and are being developed for established in Annex I, Decree 150/92,
Pharmazz is a biopharmaceutical the US and other markets. Sun Pharma will there will be no barriers to the entry of Mr. Arunish Chawla, Secretary, Pricing Authority (NPPA). The deci-
company developing its two leading drug also receive the exclusive right to license Indian products. Such products may be Department of Pharmaceuticals, has sion was approved by the Appoint-
candidates, Sovateltide for treatment of Sovateltide for marketing & distribution authorised under the simplifi ed system been assigned the additional role of ments Committee of the Cabinet (ACC)
acute cerebral ischemic stroke and Cen- in certain emerging market countries. as per norms in Argentina. Since India Chairman, National Pharmaceutical vide an order dated August 1, 2024.

150 Chemical Weekly September 3, 2024 Chemical Weekly September 3, 2024 151

Contents Index to Advertisers Index to Products Advertised